Biodexa announces positive top line phase i clinical trial results for diffuse midline glioma and provides r&d update

Biodexa pharmaceuticals plc (“biodexa” or the “company”) biodexa announces positive top line phase i clinical trial results for diffuse midline glioma and provides r&d update median overall survival of 16.5 months vs 10.0 months in comparable cohort cardiff, united kingdom, february 23, 2024 (globe newswire) – biodexa pharmaceuticals plc, (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including type 1 diabetes and rare / orphan brain cancers, announces an r&d update including positive top-line clinical trial results of a recently completed phase 1 study of mtx110 in patients with diffuse midline glioma, or dmg, and results of a preclinical experiment designed to demonstrate tolimidone's potential for beta cell proliferation in an in vitro model. mtx110 in an investigator initiated study conducted by columbia university irving medical center, patients newly diagnosed with dmg were administered mtx110 via convection enhanced delivery (“ced”) using a subcutaneous pump connected to a catheter directly implanted into the pons in a 3+3 dose-escalating design (nct 04264143).
BDRX Ratings Summary
BDRX Quant Ranking